Encouraging Survival Data For Lynparza in Metastatic Breast Cancer
OlympiAD data update backs AZ/Merck & Co.'s PARP inhibitor in metastatic breast cancer, but study not powered to give definitive answer about its effects on overall survival.
You may also be interested in...
Keeping Track: Pfizer’s Talzenna Ensures Record Year For Novel US Approvals; Novartis Submits SMA Gene Therapy
The latest drug development news and highlights from our FDA Performance Tracker.
The PARP inhibitor, acquired with Medivation, will launch in a field where Pfizer already has commercial experience through its CDK4/6 inhibitor Ibrance.
Takeda’s global blockbuster GI drug Entyvio has been approved in Japan, although its local sales prospects appear limited, while two novel cancer drugs from AstraZeneca and a world-first indication have also been cleared by the health ministry.